Company News: GlaxoSmithKline and Covidien

Share this article:

GlaxoSmithKline reported steady second-quarter revenue, with total “underlying sales” growth as being up 5%. Accounting for some of this increase in sales was the pharma's pandemic flu products, as well as type 2 diabetes drug Avandia, and genital herpes drug Valtrex. US revenues grew by about 3%, much in part driven by sales for Advair, indicated for the treatment of asthma and COPD.

Covidien has released Q3 revenue information, reporting net sales as being up 14%, and an increase of medical device sales by 22%. The company did not include any significant pipeline updates in its third-quarter report. 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.